MY176357A - N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 - Google Patents

N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2

Info

Publication number
MY176357A
MY176357A MYPI2016702327A MYPI2016702327A MY176357A MY 176357 A MY176357 A MY 176357A MY PI2016702327 A MYPI2016702327 A MY PI2016702327A MY PI2016702327 A MYPI2016702327 A MY PI2016702327A MY 176357 A MY176357 A MY 176357A
Authority
MY
Malaysia
Prior art keywords
shp2
activity
inhibiting
compositions
azaspirocycloalkane
Prior art date
Application number
MYPI2016702327A
Inventor
Christine Hiu-Tung Chen
Bakary-Barry Toure
Zhuoliang Chen
Michael Dore
Jorge Garcia Fortanet
Rajesh Karki
Mitsunori Kato
Matthew J Lamarche
Lawrence Blas Perez
Troy Douglas Smith
Sarah Williams
John William Giraldes
Martin Sendzik
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY176357A publication Critical patent/MY176357A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to compounds of formula 1: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
MYPI2016702327A 2014-01-17 2015-01-16 N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 MY176357A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461928754P 2014-01-17 2014-01-17
US201461991129P 2014-05-09 2014-05-09

Publications (1)

Publication Number Publication Date
MY176357A true MY176357A (en) 2020-08-03

Family

ID=52462974

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016702327A MY176357A (en) 2014-01-17 2015-01-16 N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2

Country Status (42)

Country Link
US (6) US10077276B2 (en)
EP (1) EP3094628B1 (en)
JP (1) JP6534389B2 (en)
KR (2) KR102501558B1 (en)
CN (1) CN105916845B (en)
AP (1) AP2016009299A0 (en)
AR (1) AR100033A1 (en)
AU (1) AU2015207757B8 (en)
BR (1) BR112016016432B1 (en)
CA (1) CA2935695C (en)
CL (1) CL2016001790A1 (en)
CR (2) CR20160328A (en)
CU (1) CU24424B1 (en)
CY (1) CY1121155T1 (en)
DK (1) DK3094628T3 (en)
DO (1) DOP2016000177A (en)
EA (1) EA031573B1 (en)
EC (1) ECSP16067692A (en)
ES (1) ES2695242T3 (en)
GT (1) GT201600147A (en)
HR (1) HRP20181832T1 (en)
HU (1) HUE039869T2 (en)
IL (1) IL246436B (en)
JO (1) JO3517B1 (en)
LT (1) LT3094628T (en)
MA (1) MA39282B1 (en)
MX (1) MX356895B (en)
MY (1) MY176357A (en)
NI (1) NI201600101A (en)
NZ (1) NZ721598A (en)
PE (1) PE20170011A1 (en)
PH (1) PH12016501336B1 (en)
PL (1) PL3094628T3 (en)
PT (1) PT3094628T (en)
RS (1) RS57757B1 (en)
SG (1) SG11201605272SA (en)
SI (1) SI3094628T1 (en)
SV (1) SV2016005245A (en)
TN (1) TN2016000268A1 (en)
TW (1) TWI657083B (en)
UY (1) UY35957A (en)
WO (1) WO2015107495A1 (en)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357184B2 (en) * 2012-06-21 2019-07-23 Globus Medical, Inc. Surgical tool systems and method
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
LT2951183T (en) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
EP3094629B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
CN107787226A (en) * 2015-03-25 2018-03-09 诺华股份有限公司 Drug regimen
US10287266B2 (en) * 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
JP6878316B2 (en) * 2015-06-19 2021-05-26 ノバルティス アーゲー Compounds and compositions for inhibiting the activity of SHP2
CN105503725B (en) * 2015-12-30 2018-03-27 天津药明康德新药开发有限公司 A kind of preparation method of the carboxylate of 1 hydroxyl of the tert-butyl group, 8 aza spiro alkane [4,5] certain herbaceous plants with big flowers alkane 8
JP7044375B2 (en) * 2016-05-31 2022-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Heterocyclic inhibitor of PTPN11
EA202092442A3 (en) * 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. NEW HETEROCYCLIC DERIVATIVES USED AS SHP2 INHIBITORS
AU2017283769B2 (en) 2016-06-14 2019-08-15 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
PH12019500056B1 (en) * 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
EA201990424A1 (en) * 2016-08-01 2019-08-30 Аптиникс Инк. SPIRALACTAM MODULERS OF NMDA RECEPTOR AND THEIR APPLICATION
MX385336B (en) 2016-08-01 2025-03-18 Aptinyx Inc NMDA SPIRO-LACTAM RECEPTOR MODULATORS AND THEIR USE.
ES2974090T3 (en) 2016-08-01 2024-06-25 Tenacia Biotechnology Hong Kong Co Ltd Spirolactam NMDA modulators and methods of use thereof
WO2018057884A1 (en) 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW202500565A (en) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2 phosphatase inhibitors and methods of use thereof
EP3568204B1 (en) 2017-01-10 2023-08-30 Novartis AG Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor
BR112019015075A2 (en) 2017-01-23 2020-03-10 Revolution Medicines, Inc. BICYCLIC COMPOUNDS AS ALLOSTIC SHP2 INHIBITORS
SG11201906412SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
WO2018172984A1 (en) * 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
GB2577436B (en) * 2017-06-20 2024-11-27 Control Components Multi-stage, multi-path rotary disc valve
JP7356414B2 (en) * 2017-09-07 2023-10-04 レヴォリューション・メディスンズ，インコーポレイテッド SHP2 inhibitor compositions and methods for treating cancer
CN118684652A (en) * 2017-09-11 2024-09-24 克鲁松制药公司 Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
WO2019067843A1 (en) 2017-09-29 2019-04-04 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
TWI697490B (en) * 2017-12-06 2020-07-01 大陸商北京加科思新藥研發有限公司 Novel heterocyclic derivatives useful as shp2 inhibitors
CA3084058A1 (en) * 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
US11426422B2 (en) 2018-01-30 2022-08-30 Research Development Foundation SHP2 inhibitors and methods of use thereof
JP7210599B2 (en) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド Spirolactam-based NMDA receptor modulators and uses thereof
CN115448923B (en) * 2018-02-13 2024-03-22 上海青煜医药科技有限公司 Pyrimidine-fused ring compound, preparation method and application thereof
MA51845A (en) * 2018-02-13 2020-12-23 Shanghai Blueray Biopharma Co Ltd CYCLIC COMPOUND MERGED WITH A PYRIMIDINE, ITS PREPARATION PROCESS AND ITS APPLICATION
WO2019165073A1 (en) 2018-02-21 2019-08-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
KR102753101B1 (en) 2018-03-02 2025-01-09 오츠카 세이야쿠 가부시키가이샤 pharmaceutical compounds
KR102724968B1 (en) 2018-03-21 2024-10-31 수조우 푸허 바이오파마 컴퍼니 리미티드 SHP2 inhibitors and uses thereof
WO2019183364A1 (en) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
CN117263942A (en) 2018-03-21 2023-12-22 传达治疗有限公司 SHP2 phosphatase inhibitors and methods of use
CN112203689A (en) * 2018-04-10 2021-01-08 锐新医药公司 SHP2 inhibitor compositions and methods for treating cancer
CN118978535A (en) 2018-05-01 2024-11-19 锐新医药公司 C40-, C28- and C-32-linked rapamycin analogs as mTOR inhibitors
JP7297871B2 (en) 2018-05-02 2023-06-26 ナビール ファーマ，インコーポレイティド Substituted heterocyclic inhibitors of PTPN11
CN116003321A (en) * 2018-05-09 2023-04-25 北京加科思新药研发有限公司 Novel heterocyclic derivatives useful as SHP2 inhibitors
SG11202100719YA (en) 2018-07-24 2021-02-25 Taiho Pharmaceutical Co Ltd Heterobicyclic compounds for inhibiting the activity of shp2
WO2020033828A1 (en) 2018-08-10 2020-02-13 Board Of Regents, The University Of Texas System 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
CN112839935A (en) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 Novel heterocyclic derivatives useful as SHP2 inhibitors
EP3856744A1 (en) * 2018-09-29 2021-08-04 Novartis AG Manufacture of compounds and compositions for inhibiting the activity of shp2
CA3113379A1 (en) * 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
TW202028183A (en) * 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 Nitrogen-containing heteroaryl derivative regulators, preparation method and application thereof
JP7449282B2 (en) 2018-10-17 2024-03-13 アレイ バイオファーマ インコーポレイテッド Protein tyrosine phosphatase inhibitors
CN117143079A (en) 2018-11-06 2023-12-01 上海奕拓医药科技有限责任公司 A kind of spiroaromatic compound and its application
CN111153899B (en) * 2018-11-08 2023-12-01 四川科伦博泰生物医药股份有限公司 A substituted pyridine compound, its preparation method and use
EP3889153A4 (en) 2018-11-30 2022-09-07 Tuojie Biotech (Shanghai) Co., Ltd. PYRIMIDINE AND PENTAGONAL HETEROCYCLE DERIVATIVE OF NITROGEN, METHOD FOR THE PREPARATION AND MEDICAL APPLICATIONS
CA3112129A1 (en) 2018-12-05 2020-06-11 Mirati Therapeutics, Inc. Combination therapies
WO2020156242A1 (en) * 2019-01-31 2020-08-06 贝达药业股份有限公司 Shp2 inhibitor and application thereof
US20220152026A1 (en) * 2019-02-12 2022-05-19 Novartis Ag Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
CA3129031A1 (en) 2019-02-12 2020-08-20 Novartis Ag Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
IL284835B2 (en) 2019-02-12 2025-08-01 Novartis Ag Pharmaceutical combination containing TNO155 and ribociclib
CN111647000B (en) 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 Pyrazine derivative and application thereof in inhibition of SHP2
EP3935049A1 (en) 2019-03-07 2022-01-12 Merck Patent GmbH Carboxamide-pyrimidine derivatives as shp2 antagonists
IL320682A (en) * 2019-04-02 2025-07-01 Array Biopharma Inc Protein tyrosine phosphatase inhibitors
US11001561B2 (en) 2019-04-08 2021-05-11 Merck Patent Gmbh Pyrimidinone derivatives as SHP2 antagonists
CN114126620B (en) 2019-05-13 2024-12-31 传达治疗有限公司 FGFR inhibitors and methods of use thereof
CN114190090A (en) * 2019-06-07 2022-03-15 锐新医药公司 Solid forms of the SHP2 inhibitor {6- [ (2-amino-3-chloropyridin-4-yl) sulfanyl ] -3- [ (3S,4S) -4-amino-3-methyl-2-oxa-8-azaspiro [4.5] decan-8-yl ] -5-methylpyrazin-2-yl } methanol
TWI817018B (en) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 Compounds for the treatment of braf-associated diseases and disorders
CA3144284A1 (en) 2019-06-28 2020-12-30 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
CN111704611B (en) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 Aryl spiro SHP2 inhibitor compound, preparation method and application
CN112300160A (en) * 2019-08-01 2021-02-02 上海奕拓医药科技有限责任公司 Spiro aromatic ring compound, preparation and application thereof
EP3772513A1 (en) 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Shp2 inhibitors
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2021061706A1 (en) 2019-09-24 2021-04-01 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of making and using the same
PE20230249A1 (en) 2019-11-08 2023-02-07 Revolution Medicines Inc BICYCLIC HETEROARYL COMPOUNDS AND THEIR USES
WO2021143823A1 (en) * 2020-01-16 2021-07-22 浙江海正药业股份有限公司 Pyridine or pyrimidine derivative, and preparation method therefor and use thereof
CN113135910A (en) 2020-01-19 2021-07-20 北京诺诚健华医药科技有限公司 Pyrimidine-4 (3H) -ketone heterocyclic compound, preparation method and pharmaceutical application thereof
EP4110338A1 (en) 2020-02-28 2023-01-04 Novartis AG A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
TW202144334A (en) * 2020-04-03 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 The crystal form of the free alkali of nitrogen-containing aromatic derivatives
CN113493440B (en) * 2020-04-03 2024-08-23 上海翰森生物医药科技有限公司 Salt of nitrogen-containing heteroaromatic derivative and crystal form thereof
WO2021218755A1 (en) * 2020-04-30 2021-11-04 贝达药业股份有限公司 Shp2 inhibitor, and composition and use thereof
CA3179994A1 (en) 2020-05-08 2021-11-11 Novartis Ag Pharmaceutical combination comprising tno155 and nazartinib
US20230218765A1 (en) * 2020-05-19 2023-07-13 The Regents Of The University Of Michigan Small molecule degraders of shp2 protein
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
CN115734966B (en) * 2020-06-12 2025-07-18 石药集团中奇制药技术（石家庄）有限公司 Heterocyclic compounds and their use
KR20230042600A (en) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Methods of Delaying, Preventing, and Treating Acquired Resistance to RAS Inhibitors
EP4169913A4 (en) 2020-06-22 2024-10-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Substituted pyrazine compound, pharmaceutical composition comprising same, and use thereof
CN115916786B (en) 2020-07-08 2025-10-17 诺华股份有限公司 Manufacture of compounds and compositions for inhibiting SHP2 activity
WO2022006780A1 (en) * 2020-07-08 2022-01-13 Novartis Ag Manufacture of compounds and compositions for inhibiting activity of shp2
EP4186896A4 (en) * 2020-07-24 2024-08-07 Betta Pharmaceuticals Co., Ltd SHP2 INHIBITOR AND COMPOSITION AND USE THEREOF
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
AU2021345111B2 (en) 2020-09-15 2025-11-27 Revolution Medicines, Inc. Indole derivatives as Ras inhibitors in the treatment of cancer
CN116348466B (en) * 2020-09-23 2025-05-30 上海齐鲁制药研究中心有限公司 Pyrazine thiobiphenyl compounds and their applications
WO2022109577A1 (en) 2020-11-18 2022-05-27 Relay Therapeutics, Inc. Fgfr inhibitors and methods of making and using the same
EP4039685A1 (en) 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors
US20240025924A1 (en) * 2021-03-23 2024-01-25 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Heterocycle substituted ketone derivative, and composition and medicinal use thereof
CN117083285A (en) * 2021-03-31 2023-11-17 南京明德新药研发有限公司 A series of Se-containing pyrazine compounds and their applications
TWI825637B (en) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors
EP4067358A1 (en) 2021-04-02 2022-10-05 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
CR20230558A (en) 2021-05-05 2024-01-24 Revolution Medicines Inc RAS INHIBITORS FOR CANCER TREATMENT
EP4333847A1 (en) 2021-05-05 2024-03-13 Novartis AG Compounds and compositions for the treatment of mpnst
AR125782A1 (en) 2021-05-05 2023-08-16 Revolution Medicines Inc RAS INHIBITORS
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
US12390469B2 (en) 2021-05-05 2025-08-19 Huyabio International, Llc SHP2 inhibitor monotherapy and uses thereof
AU2022271243A1 (en) 2021-05-05 2023-11-30 Huyabio International, Llc Combination therapies comprising shp2 inhibitors and pd-1 inhibitors
CN117642166A (en) 2021-06-09 2024-03-01 中外制药株式会社 Combination therapies for cancer treatment
EP4351582B1 (en) 2021-06-09 2025-10-08 F. Hoffmann-La Roche AG Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
TW202317100A (en) 2021-06-23 2023-05-01 瑞士商諾華公司 Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers
CA3224155A1 (en) * 2021-07-07 2023-01-12 Lei Fan Synthesis and application of phosphatase degrader
EP4395769A1 (en) 2021-09-01 2024-07-10 Novartis AG Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
EP4426305A1 (en) 2021-11-04 2024-09-11 F. Hoffmann-La Roche AG Novel use of quinazolinone compound for the treatment of cancer
TW202342040A (en) 2022-02-21 2023-11-01 瑞士商諾華公司 Pharmaceutical formulation
CN114524772B (en) * 2022-02-28 2023-07-11 中国药科大学 Heterocyclic series compound and preparation method and application thereof
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN116903581B (en) * 2022-04-14 2026-04-14 山东大学 SHP2/HDAC double-target inhibitor and preparation method and application thereof
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024035830A1 (en) 2022-08-11 2024-02-15 Relay Therapeutics, Inc. Solid forms of a cdk inhibitor
EP4345101A1 (en) 2022-09-29 2024-04-03 Irbm S.P.A. Azole derivatives as shp2 inhibitors
US20240197715A1 (en) 2022-11-18 2024-06-20 Novartis Ag Pharmaceutical combinations and uses thereof
WO2024113194A1 (en) * 2022-11-30 2024-06-06 Canwell Biotech Limited Shp2 inhibitors, compositions and methods thereof
WO2024126660A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
EP4688790A1 (en) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024218632A1 (en) 2023-04-17 2024-10-24 Array Biopharma Inc. Erk protein kinase inhibitors
CN121712509A (en) 2023-05-04 2026-03-20 锐新医药公司 Combination therapy for RAS related diseases or conditions
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024321817A1 (en) 2023-08-08 2026-03-05 Quanta Therapeutics, Inc. Combination therapies with kras modulators
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic ras inhibitors
WO2025106901A1 (en) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025215527A2 (en) 2024-04-10 2025-10-16 Novartis Ag Pharmaceutical combinations and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025261943A1 (en) 2024-06-18 2025-12-26 F. Hoffmann-La Roche Ag Anti-cancer combinations comprising mosperafenib and folfox or folfiri
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026060400A1 (en) 2024-09-16 2026-03-19 Quanta Therapeutics, Inc. Combination therapies with kras modulators
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
CN119039223B (en) * 2024-10-31 2025-02-25 江苏豪森药业集团有限公司 A preparation method of nitrogen-containing heteroaromatic derivatives and intermediates thereof
CN119661551B (en) * 2024-12-16 2025-11-25 重庆大学 A method for preparing (3R,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine hydrochloride

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (en) 1964-04-29 1967-10-15 Nestle Sa Process for the preparation of high molecular weight inclusion compounds
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
JPS6041077B2 (en) 1976-09-06 1985-09-13 喜徳 喜谷 Cis platinum(2) complex of 1,2-diaminocyclohexane isomer
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
DE3381783D1 (en) 1982-03-03 1990-09-13 Genentech Inc HUMAN ANTITHROMBIN III, DNA SEQUENCES THEREFOR, EXPRESSION AND CLONING VECTORS CONTAINING SUCH SEQUENCES AND THEREFORE TRANSFORMED CELL CULTURES, METHOD FOR EXPRESSING HUMAN ANTITHROMBIN III AND THESE CONTAINERS.
US4512991A (en) * 1982-12-27 1985-04-23 Merck & Co., Inc. 3-Acyl-2-amino-5-halo-6-(substituted)pyrazine antimicrobial compounds
FR2567518B1 (en) 1984-07-11 1987-11-13 Sanofi Sa NOVEL NITROGEN HETEROCYCLIC CORE COMPOUNDS, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THE SAME
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
EP0799617A3 (en) * 1986-02-24 1997-11-12 Mitsui Petrochemical Industries, Ltd. Therapeutic agent for neurological diseases
US5266573A (en) 1989-08-07 1993-11-30 Elf Sanofi Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
KR0166088B1 (en) 1990-01-23 1999-01-15 . Cyclodextrin derivatives with increased water solubility and uses thereof
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DK169008B1 (en) 1990-06-01 1994-07-25 Holec Lk A S Method and screen for shielding a current transformer as well as current transformers with such shielding
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738749D1 (en) 1996-08-16 2008-07-17 Schering Corp CELL SURFACE ANTIGEN FROM MAMMALS AND RELATED REAGENTS
MA26473A1 (en) 1997-03-01 2004-12-20 Glaxo Group Ltd PHARMACOLOGICALLY ACTIVE COMPOUNDS.
WO1999020758A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
JP2002502607A (en) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same
WO2000059893A1 (en) 1999-04-06 2000-10-12 Krenitsky Pharmaceuticals Inc. Neurotrophic thio substituted pyrimidines
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
PT1196186E (en) 1999-07-12 2008-02-14 Genentech Inc Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP4272338B2 (en) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト Pyridine derivatives
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
DK1438053T3 (en) 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidine derivatives, drug containing these compounds, their use and methods for their preparation
BR0307544A (en) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Phosphorus-containing compounds, components and composition as well as their use by treatment methods
RU2004126671A (en) 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) HETEROARYL COMPOUNDS USEFUL AS GSK-3 INHIBITORS
JP4201716B2 (en) 2002-03-05 2008-12-24 メルク フロスト カナダ リミテツド Cathepsin cysteine protease inhibitor
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
GB0300783D0 (en) 2003-01-14 2003-02-12 Btg Int Ltd Treatment of neurodegenerative conditions
US7393858B2 (en) 2003-03-07 2008-07-01 Merck Sharp & Dohme Ltd. Tetrahydropyran compounds as tachykinin antagonists
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20050048054A1 (en) 2003-07-11 2005-03-03 Shino Hanabuchi Lymphocytes; methods
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
KR20070008674A (en) 2004-04-01 2007-01-17 아스테라스 세이야쿠 가부시키가이샤 Pyrazine Derivatives, and Their Pharmaceutical Uses as Adenosine Antagonists
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
US20060002932A1 (en) 2004-06-04 2006-01-05 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
KR20200019263A (en) 2004-09-02 2020-02-21 제넨테크, 인크. Pyridyl inhibitors of hedgehog signalling
AU2005316540A1 (en) 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
PL2161336T5 (en) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
BRPI0615880A2 (en) 2005-09-13 2011-05-31 Palau Pharma Sa 2-aminopyrimidine-derived compounds as modulators of histamine h4 receptor activity, their use and pharmaceutical composition
AR057579A1 (en) * 2005-11-23 2007-12-05 Merck & Co Inc SPIROCICLICAL COMPOUNDS AS INHIBITORS OF ACETYLASE HISTONE (HDAC)
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
US20100029941A1 (en) 2006-03-28 2010-02-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
ES2500165T3 (en) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Biaryl compositions and methods to modulate a kinase cascade
US7515405B2 (en) 2006-07-25 2009-04-07 Hewlett-Packard Development Company, L.P. Anti-rotation mechanism for an electronic device
US20090137549A1 (en) 2006-11-09 2009-05-28 Paul John Edward Novel compounds useful for the treatment of degenerative & inflamatory diseases
US8252803B2 (en) 2007-02-12 2012-08-28 Merck Sharp & Dohme Corp. Piperidine derivatives
EP2137162B1 (en) * 2007-03-15 2018-08-01 Novartis AG Organic compounds and their uses
KR101586617B1 (en) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. Antibodies to human programmed death receptor PD-1
CN101801413A (en) 2007-07-12 2010-08-11 托勒克斯股份有限公司 Combination therapies employing GITR binding molecules
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
RU2531758C2 (en) 2008-02-11 2014-10-27 Куретек Лтд. Monoclonal antibodies for tumour treatment
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP2011518219A (en) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド Inhibitors of protein kinases
EA201100136A1 (en) 2008-06-13 2011-08-30 Новартис Аг 2,4'-BIPIRIDINILES AS PROTEINKINASE DIOR INHIBITORS APPLICABLE FOR THE TREATMENT OF HEART FAILURE AND CANCER
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102203074A (en) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 Aryl GPR119 agonists and uses thereof
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
GB0812031D0 (en) 2008-07-01 2008-08-06 7Tm Pharma As Thiazole derivatives
KR20110044992A (en) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TVF-β antagonist multi-target binding protein
WO2010011666A2 (en) 2008-07-21 2010-01-28 University Of South Florida Indoline scaffold shp-2 inhibitors and cancer treatment method
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
JP2012500652A (en) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Targeted costimulatory polypeptides and methods of use for treating cancer
ES2545609T3 (en) 2008-08-25 2015-09-14 Amplimmune, Inc. PD-1 antagonist compositions and methods of use
CN102149820B (en) 2008-09-12 2014-07-23 国立大学法人三重大学 Cells capable of expressing exogenous GITR ligands
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5702293B2 (en) * 2008-11-10 2015-04-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Compounds useful as inhibitors of ATR kinase
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
KR20100067046A (en) 2008-12-10 2010-06-18 동화약품주식회사 The novel 2, 6-substituted 3-nitropyridine derivatives, the preparation thereof and pharmaceutical composition comprising the same
FR2941696B1 (en) 2009-02-05 2011-04-15 Sanofi Aventis AZASPIRANYL-ALKYLCARBAMATES DERIVATIVES OF 5-CHAIN HETEROCYCLES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
NZ598262A (en) 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
PT3023438T (en) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anti-gitr antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
US8673913B2 (en) 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011078143A1 (en) 2009-12-22 2011-06-30 塩野義製薬株式会社 Pyrimidine derivatives and pharmaceutical composition containing same
SI2519543T1 (en) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
KR101789129B1 (en) 2010-06-30 2017-11-20 후지필름 가부시키가이샤 Novel nicotinamide derivative or salt thereof
WO2012009217A1 (en) 2010-07-13 2012-01-19 Merck Sharp & Dohme Corp. Spirocyclic compounds
KR101764952B1 (en) 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ampk-activating heterocyclic compounds and methods for using the same
WO2012027495A1 (en) * 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CA2813162C (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2- derivatives as smoothened receptor modulators
RU2591195C2 (en) 2010-12-13 2016-07-10 Эррэй Биофарма Инк. Substituted n-(1h-indazole-4-yl) imidazole [1,2-a]pyridine-3- carboxamide compounds as inhibitors of tyrosine kinase type iii receptor
JP5727276B2 (en) 2011-03-04 2015-06-03 協同油脂株式会社 Grease composition and grease-filled rolling bearing
SG2014009260A (en) 2011-09-12 2014-09-26 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
WO2013096093A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
EP2858994A1 (en) 2012-06-07 2015-04-15 F. Hoffmann-La Roche AG Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
TWI633087B (en) 2012-06-13 2018-08-21 赫孚孟拉羅股份公司 New diazaspirocycloalkane and azaspirocycloalkane
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
JP6099753B2 (en) 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド Spirocyclic compound, composition thereof and pharmaceutical application thereof
WO2014160521A1 (en) * 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
WO2015092819A2 (en) 2013-12-21 2015-06-25 Nektar Therapeutics (India) Pvt. Ltd. Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
EP3094629B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
HUE057895T2 (en) 2014-05-01 2022-06-28 Celgene Quanticel Res Inc Inhibitors of lysine specific demethylase-1
US10174032B2 (en) 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
ES2741746T3 (en) 2015-06-19 2020-02-12 Novartis Ag Compounds and compositions to inhibit SHP2 activity
JP6878316B2 (en) 2015-06-19 2021-05-26 ノバルティス アーゲー Compounds and compositions for inhibiting the activity of SHP2
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
WO2017156397A1 (en) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
JP7044375B2 (en) 2016-05-31 2022-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Heterocyclic inhibitor of PTPN11
EA202092442A3 (en) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. NEW HETEROCYCLIC DERIVATIVES USED AS SHP2 INHIBITORS
PH12019500056B1 (en) 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
WO2018057884A1 (en) 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW202500565A (en) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2 phosphatase inhibitors and methods of use thereof
EP3568204B1 (en) 2017-01-10 2023-08-30 Novartis AG Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor
SG11201906412SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
BR112019015075A2 (en) 2017-01-23 2020-03-10 Revolution Medicines, Inc. BICYCLIC COMPOUNDS AS ALLOSTIC SHP2 INHIBITORS
WO2018172984A1 (en) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
JP7356414B2 (en) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ，インコーポレイテッド SHP2 inhibitor compositions and methods for treating cancer
WO2019067843A1 (en) 2017-09-29 2019-04-04 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CA3084058A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
WO2019165073A1 (en) 2018-02-21 2019-08-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
CN117263942A (en) 2018-03-21 2023-12-22 传达治疗有限公司 SHP2 phosphatase inhibitors and methods of use
CN112203689A (en) 2018-04-10 2021-01-08 锐新医药公司 SHP2 inhibitor compositions and methods for treating cancer

Also Published As

Publication number Publication date
LT3094628T (en) 2018-10-25
PT3094628T (en) 2018-11-21
ECSP16067692A (en) 2017-10-31
EP3094628A1 (en) 2016-11-23
AU2015207757A1 (en) 2016-07-07
KR20160103137A (en) 2016-08-31
US20220073537A1 (en) 2022-03-10
ES2695242T3 (en) 2019-01-02
AP2016009299A0 (en) 2016-06-30
UY35957A (en) 2015-08-31
EP3094628B1 (en) 2018-08-08
RS57757B1 (en) 2018-12-31
IL246436A0 (en) 2016-08-31
US20170015680A1 (en) 2017-01-19
US11952386B2 (en) 2024-04-09
JO3517B1 (en) 2020-07-05
MA39282A1 (en) 2018-06-29
MA39282B1 (en) 2018-10-31
CR20160328A (en) 2016-11-10
DOP2016000177A (en) 2016-09-30
US12209098B2 (en) 2025-01-28
PE20170011A1 (en) 2017-03-25
KR102688024B1 (en) 2024-07-25
DK3094628T3 (en) 2018-12-03
EA031573B1 (en) 2019-01-31
NZ721598A (en) 2018-08-31
BR112016016432B1 (en) 2022-11-29
CR20200617A (en) 2021-02-11
JP2017502993A (en) 2017-01-26
HRP20181832T1 (en) 2019-01-11
PH12016501336A1 (en) 2016-08-15
KR20230028581A (en) 2023-02-28
MX356895B (en) 2018-06-19
US10077276B2 (en) 2018-09-18
NI201600101A (en) 2016-09-06
PH12016501336B1 (en) 2019-05-17
US20220396585A1 (en) 2022-12-15
CA2935695C (en) 2022-08-30
US10968235B2 (en) 2021-04-06
AU2015207757B2 (en) 2017-04-06
US20200181168A1 (en) 2020-06-11
IL246436B (en) 2019-10-31
SV2016005245A (en) 2016-11-21
EA201691442A1 (en) 2016-12-30
TWI657083B (en) 2019-04-21
TN2016000268A1 (en) 2017-10-06
AU2015207757B8 (en) 2017-05-11
AR100033A1 (en) 2016-09-07
HUE039869T2 (en) 2019-02-28
SI3094628T1 (en) 2018-11-30
CN105916845A (en) 2016-08-31
US20210371429A1 (en) 2021-12-02
CA2935695A1 (en) 2015-07-23
US10336774B2 (en) 2019-07-02
BR112016016432A2 (en) 2017-08-08
CN105916845B (en) 2019-11-12
US20180201623A1 (en) 2018-07-19
WO2015107495A1 (en) 2015-07-23
PL3094628T3 (en) 2019-01-31
SG11201605272SA (en) 2016-08-30
TW201612170A (en) 2016-04-01
CY1121155T1 (en) 2020-05-29
KR102501558B1 (en) 2023-02-20
MX2016009223A (en) 2016-10-05
JP6534389B2 (en) 2019-06-26
AU2015207757A8 (en) 2017-05-11
CU24424B1 (en) 2019-06-04
GT201600147A (en) 2018-11-27
CL2016001790A1 (en) 2016-12-30

Similar Documents

Publication Publication Date Title
NZ721598A (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
MX2021007432A (en) Compounds and compositions for inhibiting the activity of shp2.
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
ZA201802657B (en) Crystal forms of beta-nicotinamide mononucleotide
PH12017502260A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
PH12016500003A1 (en) Compounds and compositions as inhibitors of mek
IN2014CH00247A (en)
MY185500A (en) Macrocylic pyridine derivatives
NZ725399A (en) Macrocylic pyrimidine derivatives
PH12016501864A1 (en) Chromene and 1, 1a, 2, 7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
TN2018000188A1 (en) Isoindole compounds
PH12017501369A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
TH171931A (en) N-heteroeryl compounds which are replaced by N-azaspi cycloalkanes and Elements for inhibition of SHP2 activity.
MX2014007027A (en) Use of leuprolide acetate as a modulator of proinflammatory and factor nk-kb cytokines.